Sonoma Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Sonoma Pharmaceuticals has a total shareholder equity of $6.7M and total debt of $44.0K, which brings its debt-to-equity ratio to 0.7%. Its total assets and total liabilities are $14.6M and $7.9M respectively.
Key information
0.7%
Debt to equity ratio
US$44.00k
Debt
| Interest coverage ratio | n/a |
| Cash | US$2.41m |
| Equity | US$6.69m |
| Total liabilities | US$7.93m |
| Total assets | US$14.62m |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: SNOA's short term assets ($12.5M) exceed its short term liabilities ($3.1M).
Long Term Liabilities: SNOA's short term assets ($12.5M) exceed its long term liabilities ($4.9M).
Debt to Equity History and Analysis
Debt Level: SNOA has more cash than its total debt.
Reducing Debt: SNOA's debt to equity ratio has increased from 0.2% to 0.7% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SNOA has sufficient cash runway for 6 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: SNOA is forecast to have sufficient cash runway for 5 months based on free cash flow estimates, but has since raised additional capital.